You might think you have your money in a high-yield savings account, but do you really? The national average APY on savings is just 0.58%, but you can get up to 5.0% APY online with these accounts.

View the best savings account rates here

Christian Todd Nichols net worth and biography

Christian Nichols Biography and Net Worth

SVP of Alkermes

Todd Nichols serves as Alkermes’ Senior Vice President and Chief Commercial Officer. In this role, Mr. Nichols leads the Sales, Marketing, Market Access, and Commercial Operations functions and is responsible for setting and executing the commercial strategy to assure broad awareness of and access to Alkermes’ medicines.

Mr. Nichols has more than 20 years of extensive commercial experience in the biopharmaceutical sector, spanning multiple therapeutic areas. Before joining Alkermes in 2019, he served as Vice President of Marketing and Sales, Inflammation and Immunology at Celgene, where he was responsible for developing and managing all aspects of U.S. commercial planning, brand P&L, strategy development, go-to-market modeling and launch execution for ozanimod. Prior to this role, Mr. Nichols held various marketing and sales leadership positions at Biogen, Merck and Schering-Plough (acquired by Merck in 2009).

Mr. Nichols earned a bachelor’s degree in Accounting and Business Administration from Elon University.

What is Christian Todd Nichols' net worth?: The estimated net worth of Christian Todd Nichols is at least $1.79 million as of November 27th, 2024. Mr. Nichols owns 60,703 shares of Alkermes stock worth more than $1,785,882 as of December 3rd. This net worth approximation does not reflect any other assets that Mr. Nichols may own. Learn More about Christian Todd Nichols' net worth.
How do I contact Christian Todd Nichols?: The corporate mailing address for Mr. Nichols and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on Christian Todd Nichols' contact information.
Has Christian Todd Nichols been buying or selling shares of Alkermes?: In the last ninety days, Christian Todd Nichols has sold $151,813.20 in shares of Alkermes stock. Most recently, Christian Todd Nichols sold 5,208 shares of the business's stock in a transaction on Wednesday, November 27th. The shares were sold at an average price of $29.15, for a transaction totalling $151,813.20. Following the completion of the sale, the senior vice president now directly owns 60,703 shares of the company's stock, valued at $1,769,492.45. Learn More on Christian Todd Nichols' trading history.
Who are Alkermes' active insiders?: Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (Chairman & CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.
Are insiders buying or selling shares of Alkermes?: During the last year, insiders at the sold shares 4 times. They sold a total of 85,092 shares worth more than $2,528,339.21. The most recent insider tranaction occured on November, 27th when SVP Christian Todd Nichols sold 5,208 shares worth more than $151,813.20. Insiders at Alkermes own 4.9% of the company. Learn More about insider trades at Alkermes.
Information on this page was last updated on 11/27/2024.

Christian Todd Nichols Insider Trading History at Alkermes

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/27/2024	Sell	5,208	$29.15	$151,813.20	60,703
3/18/2024	Sell	10,417	$28.10	$292,717.70	65,911
5/30/2023	Sell	27,134	$28.93	$784,986.62	40,984
6/21/2022	Sell	7,474	$28.26	$211,215.24	21,035

Christian Todd Nichols Buying and Selling Activity at Alkermes

Alkermes Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $29.42

$29.06

$29.45

50 Day Range

MA: $28.03

$25.70

$30.08

2 Week Range

Now: $29.42

$22.90

$32.88

Volume

93,058 shs

Average Volume

1,809,334 shs

Market Capitalization

$4.76 billion

P/E Ratio

15.09

Dividend Yield

N/A

Beta

0.49

Your bank is lying to you.

From MyBankTracker | Ad